Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57
Adaptive Biotechnologies recently reported strong first-quarter results, exceeding revenue expectations and reducing losses. Analysts forecast a 14% revenue increase and a decrease in losses for 2025. Price target rose to US$10.57, signaling positive valuation.